Sun Pharmaceuticals Industries Ltd share price logo

Sun Pharmaceuticals Industries Ltd (SUNPHARMA)

₹14712.19%

bell
Get free price alerts. Set up your Free investment account to get Live Prices.
Overview
Fundamentals
Q3 '23 Results
Technicals
News and Events

Insights on Sun Pharmaceuticals Industries Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, SUNPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 5 quarters, 1.98K Cr → 2.65K Cr (in ₹), with an average increase of 6.9% per quarter

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 17.07% to 17.72% in Mar 2024 quarter

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 8.92% to 8.97% in Mar 2024 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 54.48% of holdings in Mar 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Zydus Lifesciences Ltd has given 93.1% return, outperforming this stock by 41.5%

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 12.93% to 12.21% in Mar 2024 quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 12.63K Cr → 12.58K Cr (in ₹), with an average decrease of 0.3% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, SUNPHARMA stock has moved down by -2.9%

Performance

  • Day's Low

    Day's High

    ₹1,467
    ₹1,487.95
  • 52 Week's Low

    52 Week's High

    ₹977.3
    ₹1,638.85
1 Month Return-2.4 %
3 Month Return-2.93 %
1 Year Return+ 51.62 %
Previous Close₹1,504.00
Open₹1,487.95
Volume41.68L
Upper Circuit-
Lower Circuit-
Market Cap₹3,60,859.98Cr

Analyst Rating

based on 36 analysts

BUY
64.86%
Buy
24.32%
Hold
10.81%
Sell

Based on 36 analysts offering long term price targets for Sun Pharmaceuticals Industries Ltd. An average target of ₹1619.28

Source: S&P Global Market Intelligence

Company Information

Sun Pharmaceutical Industries Ltd., incorporated in 1983, is a global specialty generic pharmaceuticals company with a presence in over 150 countries. The company is headquartered in Mumbai, India, and has operations in three primary lines of business: branded formulations, specialty generics, and active pharmaceutical ingredients (API).

Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.

Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.

Share Price: ₹1471.00 per share as on 20 Jun, 2024 04:01 PM
Market Capitalisation: ₹3,60,859.98Cr as of today
Revenue: ₹11,813.33Cr as on March 2024 (Q1 24)
Net Profit: ₹2,666.59Cr as on March 2024 (Q1 24)
Listing date: 09 Feb, 1995
OrganisationSun Pharmaceuticals Industries Ltd
HeadquartersMumbai
IndustryPharmaceuticals
E-voting on sharesClick here to vote
Revital Share Price
Volini Share Price
Abzorb Share Price
Pepfiz Share Price

What's happening today

  • img

    Today's Timeline - 20 Jun

    06:47 AM

    -

    Sun Pharma receives USFDA warning letter for manufacturing practice violations at Dadra facility.

    09:30 AM

    -

    Sun Pharma's stock falls 1.71% to trade at Rs 1478.5; BSE Healthcare index down 0.04%.

    11:40 AM

    -

    Citi Research prefers Torrent Pharma and Sun Pharma as their preferred picks in Indian Pharma coverage.

Key events for Sun Pharmaceuticals Industries Ltd

  • Sun Pharma Receives USFDA Warning Letter, Stock Falls - 20 Jun, 2024

    Sun Pharmaceuticals Industries Ltd received a warning letter from the USFDA for its Dadra facility, causing the stock to fall nearly 2%. Citi Research prefers Torrent Pharma and Sun Pharma as their top picks in Indian Pharma coverage.

  • Sun Pharma Breaks Out to Record High Levels - 13 Jun, 2024

    The pharma sector has seen a fresh breakout, and Sun Pharma is offering a buying opportunity with its breakout from an elevated base. Traders can consider long positions around current levels as it has support at the 38.2% retracement line and 100 DEMA.

  • Sun Pharma Acquires Stake in Haystack Analytics - 07 Jun, 2024

    Sun Pharmaceuticals Industries Ltd, along with its subsidiaries, is set to acquire a 9.6% stake in Haystack Analytics.

  • Sun Pharma Faces Downgrades Amid Earnings Moderation Concerns - 06 Jun, 2024

    Sun Pharmaceutical Industries Ltd has seen a number of brokerages downgrade the stock due to concerns over near-term earnings moderation. The primary drivers behind these downgrades were concerns around earnings moderation following Sun Pharmas robust performance in FY24, which now sets a higher base for FY25.

  • Motilal Oswal Recommends Buy Rating for Sun Pharma - 05 Jun, 2024

    Sun Pharma reported a slight miss at the operational level in 4QFY24, but surpassed USD1b sales in global specialty segment in FY24. Motilal Oswal recommends buy rating with target price of Rs 1810 and expects an 18% earnings CAGR over FY24-26.

  • Sun Pharma Submits Marketing Authorisation Application for Nidlegy - 04 Jun, 2024

    Sun Pharma has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for Nidlegy, an investigational treatment for neoadjuvant locally advanced melanoma. The company also faces scrutiny over suspected tax evasion.

  • ICICI Securities Recommends Holding Sun Pharma with Target Price of Rs 1463 - 03 Jun, 2024

    ICICI Securities recommends holding Sun Pharmaceutical Industries Ltd with a target price of Rs 1463. The research report highlights the company's investments in waterproofing and construction chemical business, expansion of dealer and tinting machine network, and revenue-per-store growth. However, the stock currently trades at high multiples which curbs potential upside from its current levels.

  • Sun Pharma Expects High Single-Digit Growth in Top Line Revenue - 02 Jun, 2024

    Sun Pharmaceuticals Industries Ltd is projecting a high single-digit growth in its top line revenue for FY25. The company reported a consolidated total revenue from operations at Rs 48,497 crore for FY24 and will be investing in several businesses, including product launch costs in the US as the ramp-up of its global specialty business continues.

  • Sharekhan Predicts Strong Growth for Indian Pharma Industry in US Market - 01 Jun, 2024

    Financial services firm Sharekhan has projected a 12% YoY revenue increase to Rs 17,451 crore for the Indian pharmaceutical industry's US segment. Sun Pharma, Dr. Reddy's, and Cipla are top choices for investors eyeing the US market.

  • Sun Pharma Recalls Medication and Acquires Stake in IFQM - 31 May, 2024

    Sun Pharmaceutical Industries is recalling 35,069 bottles of medication used to treat high pressure inside the eye due to glaucoma or other eye diseases. Meanwhile, the company has agreed to acquire a 14.28% stake in the Indian Foundation for Quality Management for Rs 12.5 crore.

  • Sun Pharma Faces Manufacturing Issues and Recalls Medication - 30 May, 2024

    Sun Pharma faces manufacturing issues as its Dahej facility receives four observations from the USFDA, causing a 1.9% drop in share price. Additionally, Sun Pharma's US-based unit is recalling Xelpros medication for out-of-specification particulate matter test.

  • Prabhudas Lilladher Recommends Buying Sun Pharma with Target Price of Rs. 1710 - 29 May, 2024

    Sun Pharma's Q4FY24 EBIDTA was in line with the estimate, aided by domestic formulation and specialty sales. The launch of deuruxolitinib along with progress of other pipelines provides visibility to Sun Pharma's specialty pipeline beyond FY25. Prabhudas Lilladher maintains a BUY rating at TP of Rs.1710 based on 32x FY26E earnings.

  • KR Choksey Recommends Buying Sun Pharma with Target Price of Rs 1,827 - 28 May, 2024

    Sun Pharmaceutical Industries is recommended as a buy by KR Choksey with a target price of Rs 1,827. The report cites expected high single-digit growth in FY25E revenue and continued investment in R&D for building global products pipeline for both specialty and generics segments. Global specialty sales grew at 11.1% YoY to USD 271 Mn in Q4FY24.

  • Sun Pharma Adv Reports Decline in Net Sales; Indian Drugmakers to Benefit from US Drug Shortages - 27 May, 2024

    Sun Pharmaceuticals Industries subsidiary Sun Pharma Adv reported a decline in net sales for March 2024. However, Indian drugmakers are expected to benefit from the ongoing drug shortages in the US market, leading to sustained revenue growth in fiscal year 2025.

  • Sun Pharma Inaugurates New Plant in Bangladesh - 26 May, 2024

    Sun Pharmaceuticals has opened a new plant in Bangladesh, its second investment in the country. The plant has a production capacity of over 1 billion tablets and capsules per year and is the first pharmaceutical unit in any Economic Zone of Bangladesh.

  • Sun Pharma Expands Specialty Business, Inaugurates New Plant - 25 May, 2024

    Sun Pharma plans to expand its specialty business through licensing and acquisitions after the global specialty business surpassed $1 billion sales milestone in FY24. The company also decided to acquire the remaining 21.52% stake of Taro for Rs 2,891.7 crore. Sun Pharma has inaugurated a new plant in Bangladesh, which is the company's second investment in the country.

  • Sun Pharma Posts Strong Q4 Results; Analysts Positive on Stock - 24 May, 2024

    Sun Pharmaceuticals Industries Ltd has posted a strong Q4 result with a 34% YoY increase in profit. The company's focus on complex drugs and specialty offerings is providing growth visibility, while its global specialty business exceeded USD1 billion in sales. Shareholders have also approved the merger agreement between Sun Pharma and Taro.

  • Sun Pharma Reports Strong Q4 Results but Disappointing FY25 Guidance - 23 May, 2024

    Sun Pharmaceuticals Industries Ltd reported strong Q4FY24 results with a 34% YoY jump in net profit to Rs 2,654.6 crore and surpassed $1 billion in sales in the global specialty segment in FY24. However, the stock saw a sell-off due to disappointing FY25 guidance of high single-digit annual revenue growth and spike in R&D expenses.

  • Sun Pharma Reports Strong Q4 Results - 22 May, 2024

    India's largest domestic drug maker Sun Pharmaceutical Industries reported a consolidated net profit of Rs 2,654.58 crore for Q4 FY24, with US sales at $476 million. The company also recommended a final dividend of Rs 5 per equity share. Despite US formulation sales being up by 10.9% YoY, it was lower than analyst estimates. Shares surged to the day's high after declining post-earnings announcement.

Sun Pharmaceuticals Industries Ltd Valuation

Sun Pharmaceuticals Industries Ltd in the last 5 years

  • Overview

  • Trends

Lowest (19.47x)

March 23, 2020

Today (37.69x)

June 19, 2024

Industry (65.08x)

June 19, 2024

Highest (184.63x)

August 28, 2020

LowHigh

Mutual Fund Holdings

Funds Holdings
ICICI Prudential Value Discovery Fund Direct Plan GrowthICICI Prudential Value Discovery Fund Direct Plan Growth5.45%
ICICI Prudential Equity & Debt Fund Direct Plan GrowthICICI Prudential Equity & Debt Fund Direct Plan Growth4.21%
ICICI Prudential Bluechip Fund Direct Plan GrowthICICI Prudential Bluechip Fund Direct Plan Growth2.52%
ICICI Prudential India Opportunities Fund Direct GrowthICICI Prudential India Opportunities Fund Direct Growth6.92%
Nippon India Pharma Fund - Direct Plan - Growth PlanNippon India Pharma Fund - Direct Plan - Growth Plan13.37%

Shareholding Pattern

InvestorsHoldings %Prev. 1 periods3M change
Promoter Holdings
54.48%
0.00
Foreign Institutions
17.72%
0.00
Mutual Funds
12.21%
0.00
Retail Investors
8.97%
0.00
Others
6.61%
0.00

News

Trident says operations disrupted after 'massive fire' at Dhaula facility

Trident's Dhaula unit was involved in textiles and paper manufacturing, according to the company's exchange filing.

06 Jun, 2024 07:02 AM

Fire at Trident Group factory in Barnala | Chandigarh News

A fire broke out at a paper and chemical unit of Trident Ltd, a flagship company of Trident Group, at Dhaula village in Barnala district. No loss of life was re... Read more

07 Jun, 2024 05:00 AM

Trident shares rally 7% as unit acquires stake in step down subsidiary

Trident Home Textiles, the wholly owned subsidiary of Trident, made further investment in its wholly owned subsidiary namely Trident Global BV

12 Jun, 2024 01:50 PM
View More

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Sun Pharmaceuticals Industries Ltd shares.

Sun Pharmaceuticals Industries Ltd (SUNPHARMA) share price today is ₹1471

Sun Pharmaceuticals Industries Ltd is listed on NSE

Sun Pharmaceuticals Industries Ltd is listed on BSE

  • Today’s highest price of Sun Pharmaceuticals Industries Ltd is ₹1487.95.
  • Today’s lowest price of Sun Pharmaceuticals Industries Ltd is ₹1467.

PE Ratio of Sun Pharmaceuticals Industries Ltd is 37.69

PE ratio = Sun Pharmaceuticals Industries Ltd Market price per share / Sun Pharmaceuticals Industries Ltd Earnings per share

Today’s traded volume of Sun Pharmaceuticals Industries Ltd(SUNPHARMA) is 41.68L.

Today’s market capitalisation of Sun Pharmaceuticals Industries Ltd(SUNPHARMA) is ₹360859.98Cr.

Sun Pharmaceuticals Industries Ltd(SUNPHARMAPrice
52 Week High
₹1638.85
52 Week Low
₹977.3

Sun Pharmaceuticals Industries Ltd(SUNPHARMA) share price is ₹1471. It is down -10.24% from its 52 Week High price of ₹1638.85

Sun Pharmaceuticals Industries Ltd(SUNPHARMA) share price is ₹1471. It is up 50.52% from its 52 Week Low price of ₹977.3

Sun Pharmaceuticals Industries Ltd(SUNPHARMAReturns
1 Day Returns
-33%
1 Month Returns
-2.4%
3 Month Returns
-2.93%
1 Year Returns
51.62%